Evogene（EVGN）株式概要Evogene Ltd.はその子会社とともに、イスラエル、米国、欧州、アフリカで計算生物学企業として事業を展開している。 詳細EVGN ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長2/6過去の実績0/6財務の健全性5/6配当金0/6報酬収益は年間45.5%増加すると予測されています リスク分析キャッシュランウェイが1年未満である 意味のある時価総額がありません ( $6M )過去1年間で株主の希薄化が進んだ 意味のある収益がありません ( $2M )+1 さらなるリスクすべてのリスクチェックを見るEVGN Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.5659.8% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-29m12m2016201920222025202620282031Revenue US$12.0mEarnings US$2.2mAdvancedSet Fair ValueView all narrativesEvogene Ltd. 競合他社Xenetic BiosciencesSymbol: NasdaqCM:XBIOMarket cap: US$7.0mOrgenesisSymbol: OTCPK:ORGSMarket cap: US$3.4mAdaptimmune TherapeuticsSymbol: OTCPK:ADAP.YMarket cap: US$9.5mBolt BiotherapeuticsSymbol: NasdaqCM:BOLTMarket cap: US$8.3m価格と性能株価の高値、安値、推移の概要Evogene過去の株価現在の株価₪0.5652週高値₪1.6252週安値₪0.52ベータ0.741ヶ月の変化-20.67%3ヶ月変化-34.44%1年変化-64.86%3年間の変化-93.54%5年間の変化-98.42%IPOからの変化-95.89%最新ニュースお知らせ • Jun 02Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with NivolumabEvogene Ltd. announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, Biomica Ltd., in combination with Nivolumab in patients with advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC). The open-label, single-arm Phase 1 study enrolled 11 patients, with advanced solid tumors who had previously progressed following anti-PD-1 immunotherapy and was designed to evaluate the safety and tolerability of BMC128 in combination with Nivolumab. The treatment regimen included a two-week induction phase with BMC128 monotherapy, followed by 16 weeks of combination treatment with BMC128 and Nivolumab. Patients demonstrating clinical benefit were eligible to continue Nivolumab monotherapy for up to two years or until disease progression. The study successfully met its primary endpoint, demonstrating favorable safety and tolerability, with no dose-limiting toxicities observed. Preliminary clinical findings demonstrated early signs of anti-tumor activity. Five of the eleven treated patients achieved stable disease beyond the 16-week combination treatment period. Two patients remained on study through the full two-year follow-up period during Nivolumab maintenance therapy, while one patient achieved a partial response. In addition to clinical observations, translational analyses demonstrated biological signals consistent with the proposed mechanism of action of BMC128. Responding patients showed increased microbiome diversity, evidence of immune activation, and modulation of immune suppression-associated signatures. BMC128 is a rationally designed live bacterial therapeutic candidate developed to facilitate anti-tumor immune responses in patients receiving immune checkpoint inhibitors. The product consists of a defined consortium of bacterial strains selected based on Evogene's computational microbiome discovery platform and preclinical validation studies. Under the licensing agreement with Lishan Biotech, BMC128 is being further developed under the designation LS-LBP-002.Reported Earnings • May 21First quarter 2026 earnings: EPS and revenues miss analyst expectationsFirst quarter 2026 results: US$0.60 loss per share (further deteriorated from US$0.38 loss in 1Q 2025). Revenue: US$334.0k (down 86% from 1Q 2025). Net loss: US$5.88m (loss widened 127% from 1Q 2025). Revenue missed analyst estimates by 4.6%. Earnings per share (EPS) also missed analyst estimates by 122%. Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.お知らせ • May 07Evogene Ltd. to Report Q1, 2026 Results on May 20, 2026Evogene Ltd. announced that they will report Q1, 2026 results Pre-Market on May 20, 2026New Risk • Apr 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$14m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$14m free cash flow). Shareholders have been substantially diluted in the past year (81% increase in shares outstanding). Market cap is less than US$10m (US$9.98m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Revenue is less than US$5m (US$3.9m revenue).Reported Earnings • Mar 31Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: US$1.80 loss per share. Revenue: US$3.85m (down 31% from FY 2024). Net loss: US$14.2m (loss widened 6.9% from FY 2024). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) also missed analyst estimates by 74%. Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.お知らせ • Mar 27Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $4.478862 million.Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $4.478862 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 5,076,924 Price\Range: $0.8822最新情報をもっと見るRecent updatesお知らせ • Jun 02Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with NivolumabEvogene Ltd. announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, Biomica Ltd., in combination with Nivolumab in patients with advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC). The open-label, single-arm Phase 1 study enrolled 11 patients, with advanced solid tumors who had previously progressed following anti-PD-1 immunotherapy and was designed to evaluate the safety and tolerability of BMC128 in combination with Nivolumab. The treatment regimen included a two-week induction phase with BMC128 monotherapy, followed by 16 weeks of combination treatment with BMC128 and Nivolumab. Patients demonstrating clinical benefit were eligible to continue Nivolumab monotherapy for up to two years or until disease progression. The study successfully met its primary endpoint, demonstrating favorable safety and tolerability, with no dose-limiting toxicities observed. Preliminary clinical findings demonstrated early signs of anti-tumor activity. Five of the eleven treated patients achieved stable disease beyond the 16-week combination treatment period. Two patients remained on study through the full two-year follow-up period during Nivolumab maintenance therapy, while one patient achieved a partial response. In addition to clinical observations, translational analyses demonstrated biological signals consistent with the proposed mechanism of action of BMC128. Responding patients showed increased microbiome diversity, evidence of immune activation, and modulation of immune suppression-associated signatures. BMC128 is a rationally designed live bacterial therapeutic candidate developed to facilitate anti-tumor immune responses in patients receiving immune checkpoint inhibitors. The product consists of a defined consortium of bacterial strains selected based on Evogene's computational microbiome discovery platform and preclinical validation studies. Under the licensing agreement with Lishan Biotech, BMC128 is being further developed under the designation LS-LBP-002.Reported Earnings • May 21First quarter 2026 earnings: EPS and revenues miss analyst expectationsFirst quarter 2026 results: US$0.60 loss per share (further deteriorated from US$0.38 loss in 1Q 2025). Revenue: US$334.0k (down 86% from 1Q 2025). Net loss: US$5.88m (loss widened 127% from 1Q 2025). Revenue missed analyst estimates by 4.6%. Earnings per share (EPS) also missed analyst estimates by 122%. Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.お知らせ • May 07Evogene Ltd. to Report Q1, 2026 Results on May 20, 2026Evogene Ltd. announced that they will report Q1, 2026 results Pre-Market on May 20, 2026New Risk • Apr 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$14m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$14m free cash flow). Shareholders have been substantially diluted in the past year (81% increase in shares outstanding). Market cap is less than US$10m (US$9.98m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Revenue is less than US$5m (US$3.9m revenue).Reported Earnings • Mar 31Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: US$1.80 loss per share. Revenue: US$3.85m (down 31% from FY 2024). Net loss: US$14.2m (loss widened 6.9% from FY 2024). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) also missed analyst estimates by 74%. Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.お知らせ • Mar 27Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $4.478862 million.Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $4.478862 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 5,076,924 Price\Range: $0.8822Price Target Changed • Mar 20Price target decreased by 30% to US$1.75Down from US$2.50, the current price target is provided by 1 analyst. New target price is 107% above last closing price of US$0.85. Stock is down 39% over the past year. The company posted a net loss per share of US$1.80 last year.お知らせ • Feb 19Evogene Ltd. to Report Q4, 2025 Results on Mar 05, 2026Evogene Ltd. announced that they will report Q4, 2025 results on Mar 05, 2026お知らせ • Feb 10Evogene Ltd. Appoints Prof. John J. Irwin and Prof. Dan T. Major to Its Scientific Advisory BoardEvogene Ltd. announced the appointment of Prof. John J. Irwin of the University of California, San Francisco (UCSF), and Prof. Dan T. Major of Bar-Ilan University (BIU) to its Scientific Advisory Board. Prof. John J. Irwin is an Adjunct Professor in the Department of Pharmaceutical Chemistry at UCSF and a globally recognized leader in ligand discovery and virtual screening. He is the creator of foundational, open-access resources widely used across academia and industry, including ZINC, DOCK, SEA, and DUD-E. Prof. Irwin's work has been cited over 35,000 times and has had a lasting impact on modern drug discovery through data-driven and collaborative science. Prof. Dan T. Major is a Professor of Chemistry at Bar-Ilan University and a leading expert in multiscale molecular modeling. His research integrates quantum mechanics, artificial intelligence, and biotechnology to accelerate drug discovery, ag-chemical development, and materials design. Prof. Major is a pioneer in hybrid QM/MM simulations and the developer of EnzyDock and RxnNet, with more than 150 peer-reviewed publications and multiple prestigious awards recognizing the translational impact of his work.お知らせ • Jan 16Evogene Ltd. Announces CFO ChangesEvogene Ltd. reported changes in its management. Mr. Yaron Eldad, the Company’s Chief Financial Officer, notified his resignation from his position effective as of Mach 31, 2026. The resignation of Mr. Eldad was due to personal reasons and was not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company. Ms. Polina Ravzin, the Company’s VP Finance, will continue in such position and will also assume the responsibilities of the CFO. Ms. Ravzin has served as the Company’s VP Finance from 2022. Prior to joining the Company, Ms. Ravzin served as controller and assistant to the CFO at DSIT Solutions Ltd. and Acorn Energy Inc.お知らせ • Nov 06Evogene Ltd. to Report Q3, 2025 Results on Nov 20, 2025Evogene Ltd. announced that they will report Q3, 2025 results on Nov 20, 2025お知らせ • Jul 29Evogene Ltd. to Report Q2, 2025 Results on Aug 19, 2025Evogene Ltd. announced that they will report Q2, 2025 results on Aug 19, 2025お知らせ • Jun 18Evogene Ltd., Annual General Meeting, Aug 11, 2025Evogene Ltd., Annual General Meeting, Aug 11, 2025. Location: 13 gad feinstein street, park rehovot, rehovot, Israelお知らせ • Jun 10Evogene Ltd. Announces Completion of First-In-Class Foundation Model Forgenerative Molecule Design, Developed in Collaboration with Google CloudEvogene Ltd. announced the completion of its generative AI foundation model, version 1.0, for small molecule design, developed in collaboration with Google Cloud. The new model expands the existing capabilities of ChemPass AI, Evogene's tech-engine for small molecule discovery and optimization, by addressing one of the core challenges faced by both the pharmaceutical and agriculture industries: identifying novel small molecules that meet multiple complex product criteria. In both pharma and agriculture, successful product development depends on identifying molecules that meet complex performance criteria while also being patentable. Traditional discovery methods typically address these challenges sequentially, a process that reduces success probability. This breakthrough paves the way for creating highly potent, synthesizable, and patentable molecules across life-science products. Built on a large dataset of approximately 38 billion molecular structures, the model was trained and deployed using Google Cloud's advanced AI infrastructure, including high-performance GPUs and scalable storage. The result is a foundation model that not only powers Evogene's ChemPass AI but will also provide a scalable base for future enhancements. Evogene also announces that development is already underway on version 2.0 of its generative AI foundation models, with a focus on enhanced flexibility for multi-parameter optimization. The updated version will incorporate predefined, customized parameters tailored to therapeutic contexts or specific agriculture requirements. It will enable ChemPass AI to better balance complex real-world constraints, such as efficacy, toxicity, and stability, significantly improving its ability to generate molecules optimized for clinical, commercial, and regulatory success. Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including: Biomica Ltd. - developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI; Lavie Bio - developing and commercially advancing, microbiome based ag-biologicals powered by MicroBoost AI; AgPlenus Ltd. - developing next generation ag-chemicals for effective and sustainable crop protection powered by ChemPass AI; and Casterra Ag - developing and marketing superior castor seed varieties producing high yield and high-grade oil content, on an industrial scale for the biofuel and other industries powered by GeneRator AI.お知らせ • May 08Evogene Ltd. to Report Q1, 2025 Results on May 21, 2025Evogene Ltd. announced that they will report Q1, 2025 results on May 21, 2025お知らせ • Mar 06+ 1 more updateEvogene Ltd. Announces Board ChangesEvogene Ltd. announced the appointment of Mr. Nir Nimrodi as the new Chairperson of the Board, succeeding Ms. Sarit Firon, who has held the position since August 2021. Ms. Firon will continue to serve as a member of the Board. As Evogene progresses toward key milestones across its subsidiaries and programs, Mr. Nimrodi's extensive experience in scaling life sciences businesses and driving growth makes him well-suited to guide the company's next phase. His leadership will strengthen ongoing efforts and build upon the solid foundation established under Ms. Firon's tenure. Mr. Nimrodi, a member of the Evogene Board since September 2022, brings over two decades of extensive international experience across both start-ups and large global organizations within the life sciences, pharmaceutical, and biotechnology sectors. In addition, Evogene's President and CEO, Mr. Ofer Haviv, will join as member of the Board, and will remain in office until the earlier of the first annual or special general meeting of shareholders following his appointment.お知らせ • Feb 20Evogene Ltd. to Report Q4, 2024 Results on Mar 06, 2025Evogene Ltd. announced that they will report Q4, 2024 results on Mar 06, 2025お知らせ • Nov 07Evogene Ltd. to Report Q3, 2024 Results on Nov 21, 2024Evogene Ltd. announced that they will report Q3, 2024 results on Nov 21, 2024お知らせ • Sep 17Evogene Ltd. Announces Executive ChangesEvogene Ltd. reported changes in its management team: As part of an organizational restructuring, Mr. Mark Kapel, the Company's Chief Technology Officer, will conclude his employment with Evogene, effective October 31, 2024. Evogene expresses its gratitude to Mr. Kapel for his contributions during his tenure. Mr. Kapel will continue to provide consulting services to Evogene. The Chief Technology Officer's responsibilities will be divided between the Evogene's VP Computational Platform, Dr. Ilia Zhidkov, and the VP Experimental Research Center, Dr. Silvia Shaked, both of whom have been with Evogene for the past 13 years. In addition, Dr. Gabi Tarcic, will be appointed as Evogene's VP Product, effective September 22, 2024. Dr. Tarcic has extensive experience in research and development projects and as a senior executive. Since 2012 Dr. Tarcic has served in various positions at Fore Biotherapeutics (formerly NovellusDx Israel), most recently as its Chief Technology Officer. Dr. Tarcic holds a Ph.D. from The Weizmann Institute of Science, Rehovot, Israel.お知らせ • Aug 12Evogene Ltd. to Report Q2, 2024 Results on Aug 22, 2024Evogene Ltd. announced that they will report Q2, 2024 results on Aug 22, 2024お知らせ • May 11Evogene Ltd. to Report Q1, 2024 Results on May 23, 2024Evogene Ltd. announced that they will report Q1, 2024 results on May 23, 2024お知らせ • May 01Evogene Ltd., Annual General Meeting, Jun 06, 2024Evogene Ltd., Annual General Meeting, Jun 06, 2024, at 15:00 Israel Standard Time. Location: offices at 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel Rehovot Israel Agenda: To discuss Re-election of each of (a) Ms. Sarit Firon, (b) Dr. Adrian Percy, (c) Mr. Leon Y. Recanati, (d) Prof. Oded Shoseyov, (e) Mr. Dan Falk, and (f) Mr. Nir Nimrodi; as a director of the Company, until the Company’s next annual general meeting of shareholders and until his or her successor is duly elected and qualified; to approve a reverse share split of the Company’s ordinary shares; to Adoption of a new compensation policy for the Company’s office holders; to Approval of the grant of options to purchase of the Company’s Ordinary Shares; and to Approval of the re-appointment of Kost Forer Gabbay & Kasierer, registered public accounting firm, a member firm of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year ending December 31, 2024 and until the Company’s next annual general meeting of shareholders, and the authorization of the Board or the audit committee thereof to fix such accounting firm’s annual compensation.お知らせ • Mar 30Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $7.3 million.Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $7.3 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Mar 21Evogene Reports Receipt of Nasdaq Minimum Bid Price NotificationEvogene Ltd. reported that the Company received a letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq"), indicating that the Company is currently not in compliance with Nasdaq Rule 5550(a)(2), as the Company's closing bid price for its ordinary shares has been below $1.00 per share for the last 30 consecutive business days. The Nasdaq Stock Market Rules provide the Company with an additional period of 180 calendar days to regain compliance. According to the Letter, the Company has until September 16, 2024, to regain compliance with the minimum bid price requirement. The Company will regain compliance, if at any time during this 180-day period, the closing bid price of its ordinary shares is at least $1.00 for a minimum period of ten consecutive business days, in which case the Company will be provided with a written confirmation of compliance from Nasdaq and this matter will be closed. If the Company does not demonstrate compliance (with the bid price requirement or with any other listing requirements) prior to the end of the 180-day period ending September 16, 2024, the Nasdaq's staff will notify the Company that its ordinary shares will be subject to delisting. It is noted that Evogene's continued listing on Nasdaq remains a key priority for the Company. Should the situation not resolve itself over the above-mentioned timeframe, the Company intends to consider other available options to cure the deficiency and regain compliance with the minimum bid requirement within the compliance period, including potentially approving a reverse share split among other alternatives. The Letter from Nasdaq has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares on Nasdaq, and during the aforementioned cure period, the Company's ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "EVGN". It is further noted that the Letter from Nasdaq has no bearing on Evogene's listing on the Tel Aviv Stock Exchange, where its ordinary shares are traded under the ticker symbol "EVGN".Reported Earnings • Mar 08Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: US$0.52 loss per share (improved from US$0.65 loss in FY 2022). Revenue: US$5.64m (up 237% from FY 2022). Net loss: US$23.9m (loss narrowed 10% from FY 2022). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 8.0%. Revenue is forecast to grow 55% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.お知らせ • Feb 27Evogene Ltd. to Report Q4, 2023 Results on Mar 07, 2024Evogene Ltd. announced that they will report Q4, 2023 results on Mar 07, 2024お知らせ • Dec 19Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024Casterra Ag Ltd., a subsidiary of Evogene Ltd. announced the appointment of Mr. Yoash Zohar as new CEO, as of January 1, 2024, to lead the company's expansion efforts. Considering Casterra's rapid growth and its continued prospects for development, this nomination aims to strengthen its leadership and positioning in the industry. Casterra entered a new phase in its life cycle of mass production of castor seeds to support the demand for its elite varieties, addressing the bio-diesel industry's growing needs. To this end, Casterra needs to significantly increase its castor seed production capacity through existing and new subcontractors in target-market locations. Mr. Yoash Zohar, the newly appointed CEO, brings extensive experience in global agricultural projects, particularly in Africa, along with skills in castor bean cultivation. His professional qualifications align with Casterra's current focus on establishing a robust seed production system within target geographical territories to support company's expansion. Casterra's current CEO Mr. Eyal Ronen, who also serves as Evogene's EVP of Business Development, led Casterra's activities for the past year and a half and will now resume full-time position as EVP BD. Mr. Eyal Ronen will continue to serve as a director on Casterra's Board and support company management in successfully reaching its goals. Casterra has also significantly expanded its team, including experts in research and development, seed production, and customer support. This expansion is expected to drive innovation in the company's product offerings, support the anticipated seed production increase, and enhance customer service.New Risk • Nov 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$8.6m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (US$32.9m market cap).Reported Earnings • Nov 17Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: US$0.081 loss per share (improved from US$0.16 loss in 3Q 2022). Revenue: US$3.77m (up US$3.30m from 3Q 2022). Net loss: US$3.98m (loss narrowed 39% from 3Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 49%. Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.お知らせ • Nov 03Evogene Ltd. to Report Q3, 2023 Results on Nov 15, 2023Evogene Ltd. announced that they will report Q3, 2023 results on Nov 15, 2023Reported Earnings • Aug 18Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2023 results: US$0.17 loss per share (improved from US$0.21 loss in 2Q 2022). Net loss: US$7.02m (loss narrowed 20% from 2Q 2022). Revenue missed analyst estimates by 26%. Earnings per share (EPS) exceeded analyst estimates by 2.9%. Revenue is forecast to grow 62% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.New Risk • Aug 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$16m net loss in 3 years). Revenue is less than US$5m (US$2.1m revenue). Market cap is less than US$100m (US$41.0m market cap).お知らせ • Aug 01Evogene Ltd. to Report Q2, 2023 Results on Aug 17, 2023Evogene Ltd. announced that they will report Q2, 2023 results on Aug 17, 2023お知らせ • Jul 26Evogene Ltd 's ChemPass AI Tech-Engine is Introduces with New Breakthrough Machine Learning Technology for Target-Protein DiscoveryEvogene Ltd. announced the latest addition to its ChemPass AI tech-engine - a breakthrough technology for target-protein discovery. The integration of TargetSelector, a new application that streamlines target-protein discovery for active molecule identification, assists researchers in finding suitable target proteins for new products while reducing development time, resources and most importantly, increasing the probability of success. Proteins play a fundamental role in a wide array of biological processes and serve as the primary targets for developing innovative therapeutics, ag-chemical, ag-biological, and other life science solutions. The precise identification of these protein targets is pivotal in advancing research and discovery across various domains, including pharmaceuticals, agriculture, and environmental applications. The challenge of finding a target-protein that is novel, safe, and druggable from the thousands of proteins in a relevant organism is enormous. Leveraging predictive machine learning algorithms and genomic data, users gain valuable insights into product requirements such as homology, druggability, essentiality, and biological pathways, efficiently narrowing down the list of potential target-protein, thus optimizing the discovery process.お知らせ • Jul 22Biomica Ltd. Reports Interim Positive Results from Pre-Clinical Studies in its IBS ProgramBiomica Ltd. reported interim positive results from pre-clinical studies in its IBS program. The pre-clinical work was performed in collaboration with the lab of Prof. Kara Gross Margolis, Associate Director for Clinical and Translational Research for the New York University Pain Research Center and an Associate Professor in the Department of Molecular Pathobiology in the NYU College of Dentistry and the Department of Pediatrics at NYU Grossman School of Medicine. In these studies, Biomica tested two candidate therapeutic consortia of live bacterial strains, BMC426 and BMC427. Treatment with these drug candidates effectively reduced visceral pain, a major symptom of IBS. Irritable bowel syndrome, or IBS, is a chronic digestive system disorder estimated to affect 4.1% of the worldwide population1. IBS-affected individuals suffer from abdominal pain, bloating, and abnormal bowel movements; that often affect their daily functioning and quality of life. Current standard therapies for IBS are limited, particularly in relation to IBS-associated abdominal pain. Studies have pointed to associations between alterations in the gut microbiome and IBS, suggesting microbiome involvement in developing IBS symptoms2. BMC426 and BMC427 were designed based on their functional capabilities, utilizing data collected from IBS patients through research conducted at the University of North Carolina (UNC) Chapel Hill by Prof. Yehuda Ringel, Co-Founder and Chief Scientific Officer of Biomica. The data was analyzed in silico using Biomica's PRISM system, a proprietary computational platform powered by Evogene's MicroBoost AI tech-engine. Numerous functional capabilities of BMC426 and BMC427 have been successfully validated in relevant in-vitro models. Biomica is announcing positive results observed in its in-vivo pre-clinical work, which aimed to evaluate the potential of BMC426 and BMC427 in treating IBS.New Risk • Jun 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$23m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (US$2.1m revenue). Market cap is less than US$100m (US$34.2m market cap).お知らせ • May 06Evogene Ltd., Annual General Meeting, May 11, 2023Evogene Ltd., Annual General Meeting, May 11, 2023, at 15:00 Israel Standard Time. Location: 13 Gad Feinstein Street Park Rehovot Rehovot Israelお知らせ • May 05Evogene Ltd. to Report Q1, 2023 Results on May 18, 2023Evogene Ltd. announced that they will report Q1, 2023 results on May 18, 2023Reported Earnings • Mar 11Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: US$0.65 loss per share (improved from US$0.69 loss in FY 2021). Net loss: US$26.6m (loss narrowed 4.2% from FY 2021). Revenue exceeded analyst estimates by 6.7%. Earnings per share (EPS) also surpassed analyst estimates by 14%. Revenue is forecast to grow 92% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 21Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: US$0.16 loss per share (improved from US$0.19 loss in 3Q 2021). Net loss: US$6.54m (loss narrowed 14% from 3Q 2021). Revenue exceeded analyst estimates by 65%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Revenue is forecast to grow 108% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.Price Target Changed • Nov 16Price target decreased to US$6.00Down from US$6.67, the current price target is provided by 1 analyst. New target price is 733% above last closing price of US$0.72. Stock is down 69% over the past year. The company posted a net loss per share of US$0.69 last year.Seeking Alpha • Oct 12Evogene unit files for EPA approval of bio-fungicide LAV.311 for fruit rotsEvogene (NASDAQ:EVGN) said its unit Lavie Bio filed a registration package to the U.S. Environmental Protection Agency (EPA) for LAV.311, a bio-fungicide targeting fruit rots and powdery mildews. LAV.311 is based on a bacteria which is naturally present and has shown control of fruit rots and powdery mildew in grapes, strawberries, cucurbits, and fruiting vegetables, in over 30 trials conducted in the U.S., Europe and Israel, the company said in an Oct. 12 press release. "We are pleased to have reached this key product milestone and we are targeting the 2024 growing season for the commercial launch of this product," said Lavie CEO Guri Oron. EVGN -2.87% to $0.68 premarket Oct. 12Seeking Alpha • Sep 21Evogene unit launches 2nd-gen medical cannabis products in IsraelEvogene's (NASDAQ:EVGN) unit Canonic launched its second-generation medical cannabis products in Israel. The first product from this line is expected to debut for patients in early October and the rest will follow in the last quarter of the year to Q1 2023. The second-generation products are characterized by high THC and unique terpene profiles, the company said in a Sept. 21 press release. EVGN +1.33% to $0.94 premarket Sept. 21Seeking Alpha • Sep 14Lavie Bio appoints Guri Oron as CEOLavie Bio, a subsidiary of Evogene (NASDAQ:EVGN) notifies the appointment of Guri Oron as CEO of Lavie Bio, effective as of September 18, 2022. Most recently, Mr. Oron served at Viridix Ltd., an ag-tech company focused on precision irrigation.Reported Earnings • Sep 02Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2022 results: US$0.21 loss per share (down from US$0.15 loss in 2Q 2021). Net loss: US$8.82m (loss widened 42% from 2Q 2021). Revenue exceeded analyst estimates by 41%. Earnings per share (EPS) missed analyst estimates by 11%. Over the next year, revenue is forecast to grow 833%, compared to a 41% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Seeking Alpha • Aug 31Evogene GAAP EPS of -$0.42 misses by $0.23, revenue of $0.55M beats by $0.33MEvogene press release (NASDAQ:EVGN): Q2 GAAP EPS of -$0.42 misses by $0.23. Revenue of $0.55M (+292.9% Y/Y) beats by $0.33M.Seeking Alpha • Aug 25Evogene regains compliance with Nasdaq's minimum bid price requirementEvogene (NASDAQ:EVGN) said it has regained compliance with Nasdaq's listing rule, which requires the computational biology company's ordinary shares to maintain a minimum bid price of $1.00 per share. The stock exchange has determined compliance after the closing bid price per share was at $1.00 or greater for prior 10 consecutive business days. Nasdaq now considers the matter closed. Shares were trading +2.63% pre-market. Source: Press ReleaseSeeking Alpha • Aug 17Evogen stock rises after unit gets $10M investment from ICL under collaboration agreementShares of Evogene (NASDAQ:EVGN), a developer of life-science based products, rose as much as 10.2% to $1.3 in Wednesday late afternoon trading after its unit Lavie Bio entered into a collaboration agreement with specialty minerals company ICL (NYSE:ICL). Under the deal, ICL will invest $10M in Lavie Bio, which develops microbiome-based products for use in the food and agriculture industry. The Israeli companies announced the deal after hours on Tuesday. The collaboration would focus on developing bio-stimulant products to enrich the efficiency of fertilizers, they said. Evogene (EVGN) shares had pared some gains and were trading 6.8% higher as of 1522 ET, while ICL stock was -0.9% at $10.04.Reported Earnings • May 28First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.20 loss per share (down from US$0.17 loss in 1Q 2021). Net loss: US$8.28m (loss widened 25% from 1Q 2021). Revenue missed analyst estimates by 23%. Earnings per share (EPS) also missed analyst estimates by 11%. Over the next year, revenue is forecast to grow 567%, compared to a 40% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Price Target Changed • Apr 27Price target decreased to US$10.33Down from US$11.33, the current price target is an average from 3 analysts. New target price is 875% above last closing price of US$1.06. Stock is down 77% over the past year. The company posted a net loss per share of US$0.69 last year.Board Change • Mar 29High number of new directorsScientific Advisor Eran Segal was the last director to join the board, commencing their role in 2022.Seeking Alpha • Mar 22Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenusEvogene acts as a computational biology technology hub; $50M market cap, $54M cash, 5 subsidiaries (4 of which are valuable). The article discusses subsidiaries Biomica, Lavie Bio and AgPlenus. Biomica's lead product BMC128, 4 strain live microbiome consortia in immuno-oncology, is proceeding to clinical trials in Israel in Q2 2022, in combination with Bristol Myers' PD-1 Opdivo. Lavie Bio recently commercially launched result™, a microbiome-based ag-stimulant to increase yield and profitability in spring wheat. Modest initial 2022 sales are expected to increase in 2023 and beyond. AgPlenus is an ag-chemical company. Its lead product APH1 is a novel mode of action herbicide in the near "optimized lead" stage. A deal for APH1could be announced this year. The author believes that Evogene is currently undervalued. With numerous upcoming catalysts in 2022/2023, patient risk-tolerant investors could be handsomely rewarded in the next few years.Price Target Changed • Mar 12Price target decreased to US$10.33Down from US$11.33, the current price target is an average from 3 analysts. New target price is 740% above last closing price of US$1.23. Stock is down 78% over the past year. The company posted a net loss per share of US$0.69 last year.Reported Earnings • Mar 11Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: US$0.69 loss per share (up from US$0.83 loss in FY 2020). Net loss: US$27.8m (loss widened 19% from FY 2020). Revenue exceeded analyst estimates by 51%. Earnings per share (EPS) missed analyst estimates by 3.7%. Over the next year, revenue is forecast to grow 161%, compared to a 61% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Seeking Alpha • Mar 03Evogene: Computational Biology Technology Hub; Focus On Canonic (Medical Cannabis)Evogene is a computational biology company that acts a technology hub, creating life science divisions and subsidiaries. Canonic is a subsidiary focused on discovering and developing non-GMO medical cannabis products. In October 2021, Canonic commercially launched G150 and G200, its first two MetaYield medical cannabis products in Israel which appears to be a success. Canonic has Israel's largest Cannabis R&D facility, is fully licensed, owns a state of the art 22,000 square foot greenhouse and molecular labs. It is progressing preclinically (and soon clinically) with its Precise medical cannabis program focused on the treatment of pain and inflammation. Canonic has recently begun shipping its proprietary seedling plants to Portugal in anticipation of a European launch in 2023. A U.S. launch is expected in 2024.Board Change • Feb 04High number of new directorsScientific Advisor Eran Segal was the last director to join the board, commencing their role in 2022.Executive Departure • Dec 01Chief Executive Officer of AgPlenus Ltd. Douglas Eisner has left the companyDuring their tenure, earnings grew by 34% annually compared to the industry average of 11%. On the 1st of December, Douglas Eisner left the company after 1.2 years in the role. We don't have any record of a personal shareholding under Douglas' name. Douglas is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 2.67 years.Reported Earnings • Nov 19Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$7.61m (loss widened 59% from 3Q 2020). Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year.Board Change • Nov 03High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 4 experienced directors. 1 highly experienced director. Independent Director Leon Recanati is the most experienced director on the board, commencing their role in 2005. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Seeking Alpha • Sep 14Evogene's Canonic Begins Selling High THC Cannabis In Israeli Medical MarketCanonic introduces their new proprietary cannabis strains and begins limited distribution in Israel. The company will make a full commercial release of the new products in 2022. Evogene’s other subsidiary, Lavie Bio, plans a commercial release of their bio-stimulate in 2022. The company’s Q2-2021 quarterly report shows net loss and low revenues, but plenty of operating cash. I give the company a neutral rating and recommend investors watch their developments and await revenue catalysts.Reported Earnings • Aug 12Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.17 loss in 2Q 2020)Second quarter 2021 results: Net loss: US$6.21m (loss widened 47% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 4% per year.Reported Earnings • May 27First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 1Q 2020)First quarter 2021 results: Net loss: US$6.60m (loss widened 6.0% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 6% per year.Reported Earnings • Apr 05Full year 2020 earnings released: US$0.83 loss per share (vs US$0.70 loss in FY 2019)Full year 2020 results: Net loss: US$23.4m (loss widened 29% from FY 2019). Products in clinical trials Phase I: 6 Phase II: 1 Post-clinical trial products Approved (during full year): 1 Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.Price Target Changed • Feb 12Price target raised to US$15.00Up from US$9.00, the current price target is provided by 1 analyst. The new target price is 51% above the current share price of US$9.94. As of last close, the stock is up 558% over the past year.Is New 90 Day High Low • Feb 05New 90-day high: US$7.68The company is up 183% from its price of US$2.71 on 06 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.Is New 90 Day High Low • Jan 15New 90-day high: US$5.95The company is up 56% from its price of US$3.82 on 16 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 19% over the same period.Is New 90 Day High Low • Dec 29New 90-day high: US$5.63The company is up 38% from its price of US$4.08 on 29 September 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 19% over the same period.Is New 90 Day High Low • Dec 11New 90-day high: US$4.31The company is up 102% from its price of US$2.13 on 11 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.Reported Earnings • Nov 20Third quarter 2020 earnings released: US$0.18 loss per shareThird quarter 2020 results: Net loss: US$4.79m (loss widened 13% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Oct 06New 90-day high: US$4.16The company is up 304% from its price of US$1.03 on 08 July 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 5.0% over the same period.Is New 90 Day High Low • Sep 19New 90-day high: US$3.09The company is up 209% from its price of US$1.00 on 19 June 2020. The American market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period.株主還元EVGNUS BiotechsUS 市場7D-6.2%4.6%2.0%1Y-64.9%30.5%23.3%株主還元を見る業界別リターン: EVGN過去 1 年間で30.9 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: EVGNは、過去 1 年間で25.5 % のリターンを上げたUS市場を下回りました。価格変動Is EVGN's price volatile compared to industry and market?EVGN volatilityEVGN Average Weekly Movement8.2%Biotechs Industry Average Movement10.6%Market Average Movement7.2%10% most volatile stocks in US Market16.8%10% least volatile stocks in US Market3.1%安定した株価: EVGN 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: EVGNの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト199952Ofer Havivwww.evogene.comEvogene Ltd.は子会社とともに、イスラエル、米国、欧州、アフリカで計算生物学企業として事業を展開している。事業セグメントは3つ：農業、ヒトの健康、産業応用の3つのセグメントで事業を展開している。同社は、種子形質や農薬などの農業活動、および計算生成AIエンジンであるChemPass AIを活用した医薬品開発のための新規低分子化合物の設計を行っている。また、産業用ヒマシ種子の開発・商品化にも注力している。さらに、医療用大麻製品にも取り組んでいる。LMU大学ミュンヘン病院と、炎症性腸疾患（IBD）を含む、好中球の活性調節異常によって引き起こされる炎症性疾患に対する新規治療法を開発するための共同研究を行っている。同社は1999年に法人化され、イスラエルのレホボトに本社を置いている。もっと見るEvogene Ltd. 基礎のまとめEvogene の収益と売上を時価総額と比較するとどうか。EVGN 基礎統計学時価総額US$5.71m収益（TTM）-US$18.54m売上高(TTM)US$1.84m3.1xP/Sレシオ-0.3xPER（株価収益率EVGN は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計EVGN 損益計算書（TTM）収益US$1.84m売上原価US$2.71m売上総利益-US$863.00kその他の費用US$17.68m収益-US$18.54m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-1.78グロス・マージン-46.80%純利益率-1,005.42%有利子負債／自己資本比率0%EVGN の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/17 03:12終値2026/06/17 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Evogene Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Scott HenryAlliance Global PartnersDavid BegleiterDeutsche BankHoonshik YangOppenheimer & Co. Inc.1 その他のアナリストを表示
お知らせ • Jun 02Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with NivolumabEvogene Ltd. announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, Biomica Ltd., in combination with Nivolumab in patients with advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC). The open-label, single-arm Phase 1 study enrolled 11 patients, with advanced solid tumors who had previously progressed following anti-PD-1 immunotherapy and was designed to evaluate the safety and tolerability of BMC128 in combination with Nivolumab. The treatment regimen included a two-week induction phase with BMC128 monotherapy, followed by 16 weeks of combination treatment with BMC128 and Nivolumab. Patients demonstrating clinical benefit were eligible to continue Nivolumab monotherapy for up to two years or until disease progression. The study successfully met its primary endpoint, demonstrating favorable safety and tolerability, with no dose-limiting toxicities observed. Preliminary clinical findings demonstrated early signs of anti-tumor activity. Five of the eleven treated patients achieved stable disease beyond the 16-week combination treatment period. Two patients remained on study through the full two-year follow-up period during Nivolumab maintenance therapy, while one patient achieved a partial response. In addition to clinical observations, translational analyses demonstrated biological signals consistent with the proposed mechanism of action of BMC128. Responding patients showed increased microbiome diversity, evidence of immune activation, and modulation of immune suppression-associated signatures. BMC128 is a rationally designed live bacterial therapeutic candidate developed to facilitate anti-tumor immune responses in patients receiving immune checkpoint inhibitors. The product consists of a defined consortium of bacterial strains selected based on Evogene's computational microbiome discovery platform and preclinical validation studies. Under the licensing agreement with Lishan Biotech, BMC128 is being further developed under the designation LS-LBP-002.
Reported Earnings • May 21First quarter 2026 earnings: EPS and revenues miss analyst expectationsFirst quarter 2026 results: US$0.60 loss per share (further deteriorated from US$0.38 loss in 1Q 2025). Revenue: US$334.0k (down 86% from 1Q 2025). Net loss: US$5.88m (loss widened 127% from 1Q 2025). Revenue missed analyst estimates by 4.6%. Earnings per share (EPS) also missed analyst estimates by 122%. Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
お知らせ • May 07Evogene Ltd. to Report Q1, 2026 Results on May 20, 2026Evogene Ltd. announced that they will report Q1, 2026 results Pre-Market on May 20, 2026
New Risk • Apr 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$14m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$14m free cash flow). Shareholders have been substantially diluted in the past year (81% increase in shares outstanding). Market cap is less than US$10m (US$9.98m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Revenue is less than US$5m (US$3.9m revenue).
Reported Earnings • Mar 31Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: US$1.80 loss per share. Revenue: US$3.85m (down 31% from FY 2024). Net loss: US$14.2m (loss widened 6.9% from FY 2024). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) also missed analyst estimates by 74%. Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.
お知らせ • Mar 27Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $4.478862 million.Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $4.478862 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 5,076,924 Price\Range: $0.8822
お知らせ • Jun 02Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with NivolumabEvogene Ltd. announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, Biomica Ltd., in combination with Nivolumab in patients with advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC). The open-label, single-arm Phase 1 study enrolled 11 patients, with advanced solid tumors who had previously progressed following anti-PD-1 immunotherapy and was designed to evaluate the safety and tolerability of BMC128 in combination with Nivolumab. The treatment regimen included a two-week induction phase with BMC128 monotherapy, followed by 16 weeks of combination treatment with BMC128 and Nivolumab. Patients demonstrating clinical benefit were eligible to continue Nivolumab monotherapy for up to two years or until disease progression. The study successfully met its primary endpoint, demonstrating favorable safety and tolerability, with no dose-limiting toxicities observed. Preliminary clinical findings demonstrated early signs of anti-tumor activity. Five of the eleven treated patients achieved stable disease beyond the 16-week combination treatment period. Two patients remained on study through the full two-year follow-up period during Nivolumab maintenance therapy, while one patient achieved a partial response. In addition to clinical observations, translational analyses demonstrated biological signals consistent with the proposed mechanism of action of BMC128. Responding patients showed increased microbiome diversity, evidence of immune activation, and modulation of immune suppression-associated signatures. BMC128 is a rationally designed live bacterial therapeutic candidate developed to facilitate anti-tumor immune responses in patients receiving immune checkpoint inhibitors. The product consists of a defined consortium of bacterial strains selected based on Evogene's computational microbiome discovery platform and preclinical validation studies. Under the licensing agreement with Lishan Biotech, BMC128 is being further developed under the designation LS-LBP-002.
Reported Earnings • May 21First quarter 2026 earnings: EPS and revenues miss analyst expectationsFirst quarter 2026 results: US$0.60 loss per share (further deteriorated from US$0.38 loss in 1Q 2025). Revenue: US$334.0k (down 86% from 1Q 2025). Net loss: US$5.88m (loss widened 127% from 1Q 2025). Revenue missed analyst estimates by 4.6%. Earnings per share (EPS) also missed analyst estimates by 122%. Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
お知らせ • May 07Evogene Ltd. to Report Q1, 2026 Results on May 20, 2026Evogene Ltd. announced that they will report Q1, 2026 results Pre-Market on May 20, 2026
New Risk • Apr 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$14m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$14m free cash flow). Shareholders have been substantially diluted in the past year (81% increase in shares outstanding). Market cap is less than US$10m (US$9.98m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Revenue is less than US$5m (US$3.9m revenue).
Reported Earnings • Mar 31Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: US$1.80 loss per share. Revenue: US$3.85m (down 31% from FY 2024). Net loss: US$14.2m (loss widened 6.9% from FY 2024). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) also missed analyst estimates by 74%. Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.
お知らせ • Mar 27Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $4.478862 million.Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $4.478862 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 5,076,924 Price\Range: $0.8822
Price Target Changed • Mar 20Price target decreased by 30% to US$1.75Down from US$2.50, the current price target is provided by 1 analyst. New target price is 107% above last closing price of US$0.85. Stock is down 39% over the past year. The company posted a net loss per share of US$1.80 last year.
お知らせ • Feb 19Evogene Ltd. to Report Q4, 2025 Results on Mar 05, 2026Evogene Ltd. announced that they will report Q4, 2025 results on Mar 05, 2026
お知らせ • Feb 10Evogene Ltd. Appoints Prof. John J. Irwin and Prof. Dan T. Major to Its Scientific Advisory BoardEvogene Ltd. announced the appointment of Prof. John J. Irwin of the University of California, San Francisco (UCSF), and Prof. Dan T. Major of Bar-Ilan University (BIU) to its Scientific Advisory Board. Prof. John J. Irwin is an Adjunct Professor in the Department of Pharmaceutical Chemistry at UCSF and a globally recognized leader in ligand discovery and virtual screening. He is the creator of foundational, open-access resources widely used across academia and industry, including ZINC, DOCK, SEA, and DUD-E. Prof. Irwin's work has been cited over 35,000 times and has had a lasting impact on modern drug discovery through data-driven and collaborative science. Prof. Dan T. Major is a Professor of Chemistry at Bar-Ilan University and a leading expert in multiscale molecular modeling. His research integrates quantum mechanics, artificial intelligence, and biotechnology to accelerate drug discovery, ag-chemical development, and materials design. Prof. Major is a pioneer in hybrid QM/MM simulations and the developer of EnzyDock and RxnNet, with more than 150 peer-reviewed publications and multiple prestigious awards recognizing the translational impact of his work.
お知らせ • Jan 16Evogene Ltd. Announces CFO ChangesEvogene Ltd. reported changes in its management. Mr. Yaron Eldad, the Company’s Chief Financial Officer, notified his resignation from his position effective as of Mach 31, 2026. The resignation of Mr. Eldad was due to personal reasons and was not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company. Ms. Polina Ravzin, the Company’s VP Finance, will continue in such position and will also assume the responsibilities of the CFO. Ms. Ravzin has served as the Company’s VP Finance from 2022. Prior to joining the Company, Ms. Ravzin served as controller and assistant to the CFO at DSIT Solutions Ltd. and Acorn Energy Inc.
お知らせ • Nov 06Evogene Ltd. to Report Q3, 2025 Results on Nov 20, 2025Evogene Ltd. announced that they will report Q3, 2025 results on Nov 20, 2025
お知らせ • Jul 29Evogene Ltd. to Report Q2, 2025 Results on Aug 19, 2025Evogene Ltd. announced that they will report Q2, 2025 results on Aug 19, 2025
お知らせ • Jun 18Evogene Ltd., Annual General Meeting, Aug 11, 2025Evogene Ltd., Annual General Meeting, Aug 11, 2025. Location: 13 gad feinstein street, park rehovot, rehovot, Israel
お知らせ • Jun 10Evogene Ltd. Announces Completion of First-In-Class Foundation Model Forgenerative Molecule Design, Developed in Collaboration with Google CloudEvogene Ltd. announced the completion of its generative AI foundation model, version 1.0, for small molecule design, developed in collaboration with Google Cloud. The new model expands the existing capabilities of ChemPass AI, Evogene's tech-engine for small molecule discovery and optimization, by addressing one of the core challenges faced by both the pharmaceutical and agriculture industries: identifying novel small molecules that meet multiple complex product criteria. In both pharma and agriculture, successful product development depends on identifying molecules that meet complex performance criteria while also being patentable. Traditional discovery methods typically address these challenges sequentially, a process that reduces success probability. This breakthrough paves the way for creating highly potent, synthesizable, and patentable molecules across life-science products. Built on a large dataset of approximately 38 billion molecular structures, the model was trained and deployed using Google Cloud's advanced AI infrastructure, including high-performance GPUs and scalable storage. The result is a foundation model that not only powers Evogene's ChemPass AI but will also provide a scalable base for future enhancements. Evogene also announces that development is already underway on version 2.0 of its generative AI foundation models, with a focus on enhanced flexibility for multi-parameter optimization. The updated version will incorporate predefined, customized parameters tailored to therapeutic contexts or specific agriculture requirements. It will enable ChemPass AI to better balance complex real-world constraints, such as efficacy, toxicity, and stability, significantly improving its ability to generate molecules optimized for clinical, commercial, and regulatory success. Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including: Biomica Ltd. - developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI; Lavie Bio - developing and commercially advancing, microbiome based ag-biologicals powered by MicroBoost AI; AgPlenus Ltd. - developing next generation ag-chemicals for effective and sustainable crop protection powered by ChemPass AI; and Casterra Ag - developing and marketing superior castor seed varieties producing high yield and high-grade oil content, on an industrial scale for the biofuel and other industries powered by GeneRator AI.
お知らせ • May 08Evogene Ltd. to Report Q1, 2025 Results on May 21, 2025Evogene Ltd. announced that they will report Q1, 2025 results on May 21, 2025
お知らせ • Mar 06+ 1 more updateEvogene Ltd. Announces Board ChangesEvogene Ltd. announced the appointment of Mr. Nir Nimrodi as the new Chairperson of the Board, succeeding Ms. Sarit Firon, who has held the position since August 2021. Ms. Firon will continue to serve as a member of the Board. As Evogene progresses toward key milestones across its subsidiaries and programs, Mr. Nimrodi's extensive experience in scaling life sciences businesses and driving growth makes him well-suited to guide the company's next phase. His leadership will strengthen ongoing efforts and build upon the solid foundation established under Ms. Firon's tenure. Mr. Nimrodi, a member of the Evogene Board since September 2022, brings over two decades of extensive international experience across both start-ups and large global organizations within the life sciences, pharmaceutical, and biotechnology sectors. In addition, Evogene's President and CEO, Mr. Ofer Haviv, will join as member of the Board, and will remain in office until the earlier of the first annual or special general meeting of shareholders following his appointment.
お知らせ • Feb 20Evogene Ltd. to Report Q4, 2024 Results on Mar 06, 2025Evogene Ltd. announced that they will report Q4, 2024 results on Mar 06, 2025
お知らせ • Nov 07Evogene Ltd. to Report Q3, 2024 Results on Nov 21, 2024Evogene Ltd. announced that they will report Q3, 2024 results on Nov 21, 2024
お知らせ • Sep 17Evogene Ltd. Announces Executive ChangesEvogene Ltd. reported changes in its management team: As part of an organizational restructuring, Mr. Mark Kapel, the Company's Chief Technology Officer, will conclude his employment with Evogene, effective October 31, 2024. Evogene expresses its gratitude to Mr. Kapel for his contributions during his tenure. Mr. Kapel will continue to provide consulting services to Evogene. The Chief Technology Officer's responsibilities will be divided between the Evogene's VP Computational Platform, Dr. Ilia Zhidkov, and the VP Experimental Research Center, Dr. Silvia Shaked, both of whom have been with Evogene for the past 13 years. In addition, Dr. Gabi Tarcic, will be appointed as Evogene's VP Product, effective September 22, 2024. Dr. Tarcic has extensive experience in research and development projects and as a senior executive. Since 2012 Dr. Tarcic has served in various positions at Fore Biotherapeutics (formerly NovellusDx Israel), most recently as its Chief Technology Officer. Dr. Tarcic holds a Ph.D. from The Weizmann Institute of Science, Rehovot, Israel.
お知らせ • Aug 12Evogene Ltd. to Report Q2, 2024 Results on Aug 22, 2024Evogene Ltd. announced that they will report Q2, 2024 results on Aug 22, 2024
お知らせ • May 11Evogene Ltd. to Report Q1, 2024 Results on May 23, 2024Evogene Ltd. announced that they will report Q1, 2024 results on May 23, 2024
お知らせ • May 01Evogene Ltd., Annual General Meeting, Jun 06, 2024Evogene Ltd., Annual General Meeting, Jun 06, 2024, at 15:00 Israel Standard Time. Location: offices at 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel Rehovot Israel Agenda: To discuss Re-election of each of (a) Ms. Sarit Firon, (b) Dr. Adrian Percy, (c) Mr. Leon Y. Recanati, (d) Prof. Oded Shoseyov, (e) Mr. Dan Falk, and (f) Mr. Nir Nimrodi; as a director of the Company, until the Company’s next annual general meeting of shareholders and until his or her successor is duly elected and qualified; to approve a reverse share split of the Company’s ordinary shares; to Adoption of a new compensation policy for the Company’s office holders; to Approval of the grant of options to purchase of the Company’s Ordinary Shares; and to Approval of the re-appointment of Kost Forer Gabbay & Kasierer, registered public accounting firm, a member firm of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year ending December 31, 2024 and until the Company’s next annual general meeting of shareholders, and the authorization of the Board or the audit committee thereof to fix such accounting firm’s annual compensation.
お知らせ • Mar 30Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $7.3 million.Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $7.3 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Mar 21Evogene Reports Receipt of Nasdaq Minimum Bid Price NotificationEvogene Ltd. reported that the Company received a letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq"), indicating that the Company is currently not in compliance with Nasdaq Rule 5550(a)(2), as the Company's closing bid price for its ordinary shares has been below $1.00 per share for the last 30 consecutive business days. The Nasdaq Stock Market Rules provide the Company with an additional period of 180 calendar days to regain compliance. According to the Letter, the Company has until September 16, 2024, to regain compliance with the minimum bid price requirement. The Company will regain compliance, if at any time during this 180-day period, the closing bid price of its ordinary shares is at least $1.00 for a minimum period of ten consecutive business days, in which case the Company will be provided with a written confirmation of compliance from Nasdaq and this matter will be closed. If the Company does not demonstrate compliance (with the bid price requirement or with any other listing requirements) prior to the end of the 180-day period ending September 16, 2024, the Nasdaq's staff will notify the Company that its ordinary shares will be subject to delisting. It is noted that Evogene's continued listing on Nasdaq remains a key priority for the Company. Should the situation not resolve itself over the above-mentioned timeframe, the Company intends to consider other available options to cure the deficiency and regain compliance with the minimum bid requirement within the compliance period, including potentially approving a reverse share split among other alternatives. The Letter from Nasdaq has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares on Nasdaq, and during the aforementioned cure period, the Company's ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "EVGN". It is further noted that the Letter from Nasdaq has no bearing on Evogene's listing on the Tel Aviv Stock Exchange, where its ordinary shares are traded under the ticker symbol "EVGN".
Reported Earnings • Mar 08Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: US$0.52 loss per share (improved from US$0.65 loss in FY 2022). Revenue: US$5.64m (up 237% from FY 2022). Net loss: US$23.9m (loss narrowed 10% from FY 2022). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 8.0%. Revenue is forecast to grow 55% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.
お知らせ • Feb 27Evogene Ltd. to Report Q4, 2023 Results on Mar 07, 2024Evogene Ltd. announced that they will report Q4, 2023 results on Mar 07, 2024
お知らせ • Dec 19Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024Casterra Ag Ltd., a subsidiary of Evogene Ltd. announced the appointment of Mr. Yoash Zohar as new CEO, as of January 1, 2024, to lead the company's expansion efforts. Considering Casterra's rapid growth and its continued prospects for development, this nomination aims to strengthen its leadership and positioning in the industry. Casterra entered a new phase in its life cycle of mass production of castor seeds to support the demand for its elite varieties, addressing the bio-diesel industry's growing needs. To this end, Casterra needs to significantly increase its castor seed production capacity through existing and new subcontractors in target-market locations. Mr. Yoash Zohar, the newly appointed CEO, brings extensive experience in global agricultural projects, particularly in Africa, along with skills in castor bean cultivation. His professional qualifications align with Casterra's current focus on establishing a robust seed production system within target geographical territories to support company's expansion. Casterra's current CEO Mr. Eyal Ronen, who also serves as Evogene's EVP of Business Development, led Casterra's activities for the past year and a half and will now resume full-time position as EVP BD. Mr. Eyal Ronen will continue to serve as a director on Casterra's Board and support company management in successfully reaching its goals. Casterra has also significantly expanded its team, including experts in research and development, seed production, and customer support. This expansion is expected to drive innovation in the company's product offerings, support the anticipated seed production increase, and enhance customer service.
New Risk • Nov 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$8.6m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (US$32.9m market cap).
Reported Earnings • Nov 17Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: US$0.081 loss per share (improved from US$0.16 loss in 3Q 2022). Revenue: US$3.77m (up US$3.30m from 3Q 2022). Net loss: US$3.98m (loss narrowed 39% from 3Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 49%. Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
お知らせ • Nov 03Evogene Ltd. to Report Q3, 2023 Results on Nov 15, 2023Evogene Ltd. announced that they will report Q3, 2023 results on Nov 15, 2023
Reported Earnings • Aug 18Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2023 results: US$0.17 loss per share (improved from US$0.21 loss in 2Q 2022). Net loss: US$7.02m (loss narrowed 20% from 2Q 2022). Revenue missed analyst estimates by 26%. Earnings per share (EPS) exceeded analyst estimates by 2.9%. Revenue is forecast to grow 62% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
New Risk • Aug 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$16m net loss in 3 years). Revenue is less than US$5m (US$2.1m revenue). Market cap is less than US$100m (US$41.0m market cap).
お知らせ • Aug 01Evogene Ltd. to Report Q2, 2023 Results on Aug 17, 2023Evogene Ltd. announced that they will report Q2, 2023 results on Aug 17, 2023
お知らせ • Jul 26Evogene Ltd 's ChemPass AI Tech-Engine is Introduces with New Breakthrough Machine Learning Technology for Target-Protein DiscoveryEvogene Ltd. announced the latest addition to its ChemPass AI tech-engine - a breakthrough technology for target-protein discovery. The integration of TargetSelector, a new application that streamlines target-protein discovery for active molecule identification, assists researchers in finding suitable target proteins for new products while reducing development time, resources and most importantly, increasing the probability of success. Proteins play a fundamental role in a wide array of biological processes and serve as the primary targets for developing innovative therapeutics, ag-chemical, ag-biological, and other life science solutions. The precise identification of these protein targets is pivotal in advancing research and discovery across various domains, including pharmaceuticals, agriculture, and environmental applications. The challenge of finding a target-protein that is novel, safe, and druggable from the thousands of proteins in a relevant organism is enormous. Leveraging predictive machine learning algorithms and genomic data, users gain valuable insights into product requirements such as homology, druggability, essentiality, and biological pathways, efficiently narrowing down the list of potential target-protein, thus optimizing the discovery process.
お知らせ • Jul 22Biomica Ltd. Reports Interim Positive Results from Pre-Clinical Studies in its IBS ProgramBiomica Ltd. reported interim positive results from pre-clinical studies in its IBS program. The pre-clinical work was performed in collaboration with the lab of Prof. Kara Gross Margolis, Associate Director for Clinical and Translational Research for the New York University Pain Research Center and an Associate Professor in the Department of Molecular Pathobiology in the NYU College of Dentistry and the Department of Pediatrics at NYU Grossman School of Medicine. In these studies, Biomica tested two candidate therapeutic consortia of live bacterial strains, BMC426 and BMC427. Treatment with these drug candidates effectively reduced visceral pain, a major symptom of IBS. Irritable bowel syndrome, or IBS, is a chronic digestive system disorder estimated to affect 4.1% of the worldwide population1. IBS-affected individuals suffer from abdominal pain, bloating, and abnormal bowel movements; that often affect their daily functioning and quality of life. Current standard therapies for IBS are limited, particularly in relation to IBS-associated abdominal pain. Studies have pointed to associations between alterations in the gut microbiome and IBS, suggesting microbiome involvement in developing IBS symptoms2. BMC426 and BMC427 were designed based on their functional capabilities, utilizing data collected from IBS patients through research conducted at the University of North Carolina (UNC) Chapel Hill by Prof. Yehuda Ringel, Co-Founder and Chief Scientific Officer of Biomica. The data was analyzed in silico using Biomica's PRISM system, a proprietary computational platform powered by Evogene's MicroBoost AI tech-engine. Numerous functional capabilities of BMC426 and BMC427 have been successfully validated in relevant in-vitro models. Biomica is announcing positive results observed in its in-vivo pre-clinical work, which aimed to evaluate the potential of BMC426 and BMC427 in treating IBS.
New Risk • Jun 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$23m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (US$2.1m revenue). Market cap is less than US$100m (US$34.2m market cap).
お知らせ • May 06Evogene Ltd., Annual General Meeting, May 11, 2023Evogene Ltd., Annual General Meeting, May 11, 2023, at 15:00 Israel Standard Time. Location: 13 Gad Feinstein Street Park Rehovot Rehovot Israel
お知らせ • May 05Evogene Ltd. to Report Q1, 2023 Results on May 18, 2023Evogene Ltd. announced that they will report Q1, 2023 results on May 18, 2023
Reported Earnings • Mar 11Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: US$0.65 loss per share (improved from US$0.69 loss in FY 2021). Net loss: US$26.6m (loss narrowed 4.2% from FY 2021). Revenue exceeded analyst estimates by 6.7%. Earnings per share (EPS) also surpassed analyst estimates by 14%. Revenue is forecast to grow 92% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 21Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: US$0.16 loss per share (improved from US$0.19 loss in 3Q 2021). Net loss: US$6.54m (loss narrowed 14% from 3Q 2021). Revenue exceeded analyst estimates by 65%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Revenue is forecast to grow 108% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
Price Target Changed • Nov 16Price target decreased to US$6.00Down from US$6.67, the current price target is provided by 1 analyst. New target price is 733% above last closing price of US$0.72. Stock is down 69% over the past year. The company posted a net loss per share of US$0.69 last year.
Seeking Alpha • Oct 12Evogene unit files for EPA approval of bio-fungicide LAV.311 for fruit rotsEvogene (NASDAQ:EVGN) said its unit Lavie Bio filed a registration package to the U.S. Environmental Protection Agency (EPA) for LAV.311, a bio-fungicide targeting fruit rots and powdery mildews. LAV.311 is based on a bacteria which is naturally present and has shown control of fruit rots and powdery mildew in grapes, strawberries, cucurbits, and fruiting vegetables, in over 30 trials conducted in the U.S., Europe and Israel, the company said in an Oct. 12 press release. "We are pleased to have reached this key product milestone and we are targeting the 2024 growing season for the commercial launch of this product," said Lavie CEO Guri Oron. EVGN -2.87% to $0.68 premarket Oct. 12
Seeking Alpha • Sep 21Evogene unit launches 2nd-gen medical cannabis products in IsraelEvogene's (NASDAQ:EVGN) unit Canonic launched its second-generation medical cannabis products in Israel. The first product from this line is expected to debut for patients in early October and the rest will follow in the last quarter of the year to Q1 2023. The second-generation products are characterized by high THC and unique terpene profiles, the company said in a Sept. 21 press release. EVGN +1.33% to $0.94 premarket Sept. 21
Seeking Alpha • Sep 14Lavie Bio appoints Guri Oron as CEOLavie Bio, a subsidiary of Evogene (NASDAQ:EVGN) notifies the appointment of Guri Oron as CEO of Lavie Bio, effective as of September 18, 2022. Most recently, Mr. Oron served at Viridix Ltd., an ag-tech company focused on precision irrigation.
Reported Earnings • Sep 02Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2022 results: US$0.21 loss per share (down from US$0.15 loss in 2Q 2021). Net loss: US$8.82m (loss widened 42% from 2Q 2021). Revenue exceeded analyst estimates by 41%. Earnings per share (EPS) missed analyst estimates by 11%. Over the next year, revenue is forecast to grow 833%, compared to a 41% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Seeking Alpha • Aug 31Evogene GAAP EPS of -$0.42 misses by $0.23, revenue of $0.55M beats by $0.33MEvogene press release (NASDAQ:EVGN): Q2 GAAP EPS of -$0.42 misses by $0.23. Revenue of $0.55M (+292.9% Y/Y) beats by $0.33M.
Seeking Alpha • Aug 25Evogene regains compliance with Nasdaq's minimum bid price requirementEvogene (NASDAQ:EVGN) said it has regained compliance with Nasdaq's listing rule, which requires the computational biology company's ordinary shares to maintain a minimum bid price of $1.00 per share. The stock exchange has determined compliance after the closing bid price per share was at $1.00 or greater for prior 10 consecutive business days. Nasdaq now considers the matter closed. Shares were trading +2.63% pre-market. Source: Press Release
Seeking Alpha • Aug 17Evogen stock rises after unit gets $10M investment from ICL under collaboration agreementShares of Evogene (NASDAQ:EVGN), a developer of life-science based products, rose as much as 10.2% to $1.3 in Wednesday late afternoon trading after its unit Lavie Bio entered into a collaboration agreement with specialty minerals company ICL (NYSE:ICL). Under the deal, ICL will invest $10M in Lavie Bio, which develops microbiome-based products for use in the food and agriculture industry. The Israeli companies announced the deal after hours on Tuesday. The collaboration would focus on developing bio-stimulant products to enrich the efficiency of fertilizers, they said. Evogene (EVGN) shares had pared some gains and were trading 6.8% higher as of 1522 ET, while ICL stock was -0.9% at $10.04.
Reported Earnings • May 28First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.20 loss per share (down from US$0.17 loss in 1Q 2021). Net loss: US$8.28m (loss widened 25% from 1Q 2021). Revenue missed analyst estimates by 23%. Earnings per share (EPS) also missed analyst estimates by 11%. Over the next year, revenue is forecast to grow 567%, compared to a 40% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 27Price target decreased to US$10.33Down from US$11.33, the current price target is an average from 3 analysts. New target price is 875% above last closing price of US$1.06. Stock is down 77% over the past year. The company posted a net loss per share of US$0.69 last year.
Board Change • Mar 29High number of new directorsScientific Advisor Eran Segal was the last director to join the board, commencing their role in 2022.
Seeking Alpha • Mar 22Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenusEvogene acts as a computational biology technology hub; $50M market cap, $54M cash, 5 subsidiaries (4 of which are valuable). The article discusses subsidiaries Biomica, Lavie Bio and AgPlenus. Biomica's lead product BMC128, 4 strain live microbiome consortia in immuno-oncology, is proceeding to clinical trials in Israel in Q2 2022, in combination with Bristol Myers' PD-1 Opdivo. Lavie Bio recently commercially launched result™, a microbiome-based ag-stimulant to increase yield and profitability in spring wheat. Modest initial 2022 sales are expected to increase in 2023 and beyond. AgPlenus is an ag-chemical company. Its lead product APH1 is a novel mode of action herbicide in the near "optimized lead" stage. A deal for APH1could be announced this year. The author believes that Evogene is currently undervalued. With numerous upcoming catalysts in 2022/2023, patient risk-tolerant investors could be handsomely rewarded in the next few years.
Price Target Changed • Mar 12Price target decreased to US$10.33Down from US$11.33, the current price target is an average from 3 analysts. New target price is 740% above last closing price of US$1.23. Stock is down 78% over the past year. The company posted a net loss per share of US$0.69 last year.
Reported Earnings • Mar 11Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: US$0.69 loss per share (up from US$0.83 loss in FY 2020). Net loss: US$27.8m (loss widened 19% from FY 2020). Revenue exceeded analyst estimates by 51%. Earnings per share (EPS) missed analyst estimates by 3.7%. Over the next year, revenue is forecast to grow 161%, compared to a 61% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Seeking Alpha • Mar 03Evogene: Computational Biology Technology Hub; Focus On Canonic (Medical Cannabis)Evogene is a computational biology company that acts a technology hub, creating life science divisions and subsidiaries. Canonic is a subsidiary focused on discovering and developing non-GMO medical cannabis products. In October 2021, Canonic commercially launched G150 and G200, its first two MetaYield medical cannabis products in Israel which appears to be a success. Canonic has Israel's largest Cannabis R&D facility, is fully licensed, owns a state of the art 22,000 square foot greenhouse and molecular labs. It is progressing preclinically (and soon clinically) with its Precise medical cannabis program focused on the treatment of pain and inflammation. Canonic has recently begun shipping its proprietary seedling plants to Portugal in anticipation of a European launch in 2023. A U.S. launch is expected in 2024.
Board Change • Feb 04High number of new directorsScientific Advisor Eran Segal was the last director to join the board, commencing their role in 2022.
Executive Departure • Dec 01Chief Executive Officer of AgPlenus Ltd. Douglas Eisner has left the companyDuring their tenure, earnings grew by 34% annually compared to the industry average of 11%. On the 1st of December, Douglas Eisner left the company after 1.2 years in the role. We don't have any record of a personal shareholding under Douglas' name. Douglas is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 2.67 years.
Reported Earnings • Nov 19Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$7.61m (loss widened 59% from 3Q 2020). Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year.
Board Change • Nov 03High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 4 experienced directors. 1 highly experienced director. Independent Director Leon Recanati is the most experienced director on the board, commencing their role in 2005. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Seeking Alpha • Sep 14Evogene's Canonic Begins Selling High THC Cannabis In Israeli Medical MarketCanonic introduces their new proprietary cannabis strains and begins limited distribution in Israel. The company will make a full commercial release of the new products in 2022. Evogene’s other subsidiary, Lavie Bio, plans a commercial release of their bio-stimulate in 2022. The company’s Q2-2021 quarterly report shows net loss and low revenues, but plenty of operating cash. I give the company a neutral rating and recommend investors watch their developments and await revenue catalysts.
Reported Earnings • Aug 12Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.17 loss in 2Q 2020)Second quarter 2021 results: Net loss: US$6.21m (loss widened 47% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 4% per year.
Reported Earnings • May 27First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 1Q 2020)First quarter 2021 results: Net loss: US$6.60m (loss widened 6.0% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 6% per year.
Reported Earnings • Apr 05Full year 2020 earnings released: US$0.83 loss per share (vs US$0.70 loss in FY 2019)Full year 2020 results: Net loss: US$23.4m (loss widened 29% from FY 2019). Products in clinical trials Phase I: 6 Phase II: 1 Post-clinical trial products Approved (during full year): 1 Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.
Price Target Changed • Feb 12Price target raised to US$15.00Up from US$9.00, the current price target is provided by 1 analyst. The new target price is 51% above the current share price of US$9.94. As of last close, the stock is up 558% over the past year.
Is New 90 Day High Low • Feb 05New 90-day high: US$7.68The company is up 183% from its price of US$2.71 on 06 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.
Is New 90 Day High Low • Jan 15New 90-day high: US$5.95The company is up 56% from its price of US$3.82 on 16 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 19% over the same period.
Is New 90 Day High Low • Dec 29New 90-day high: US$5.63The company is up 38% from its price of US$4.08 on 29 September 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 19% over the same period.
Is New 90 Day High Low • Dec 11New 90-day high: US$4.31The company is up 102% from its price of US$2.13 on 11 September 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.
Reported Earnings • Nov 20Third quarter 2020 earnings released: US$0.18 loss per shareThird quarter 2020 results: Net loss: US$4.79m (loss widened 13% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Oct 06New 90-day high: US$4.16The company is up 304% from its price of US$1.03 on 08 July 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 5.0% over the same period.
Is New 90 Day High Low • Sep 19New 90-day high: US$3.09The company is up 209% from its price of US$1.00 on 19 June 2020. The American market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period.
